drugset / Trial / NCT03224585
Treatment of Acute Pericarditis With Anakinra
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this study is to determine the safety and efficacy of anakinra for the treatment of acute pericarditis when initiated within 6 hours of diagnosis and continued for 3 or 7 days. 1. to determine the efficacy of anakinra with respect to chest pain resolution 2. to determine the safety of anakinra with respect to adverse drug events
Timeline
- Start
- 2018-05-11
- Primary completion
- 2020-02-01
- Completion
- 2020-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anakinra | Protein / enzyme biologic | 100 mg | Subcutaneous |